Rosiglitazone belongs to a class of drugs called thiazolidinediones. It helps control blood sugar levels in patients with type 2 diabetes but it can also increase the risk of serious heart problems said the study published in the journal The BMJ. Our study suggests that when evaluating drug safety and performing meta-analyses focused on safety individual patient level data (IPD) might be necessary to accurately classify all adverse events said the study researchers By including these data in research patients clinicians and researchers would be able to make more informed decisions about the safety of interventions they added. Since 2007
